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The EVEREST Clinical Trials including EVEREST I, EVEREST II Roll-in, EVEREST II RCT, and EVEREST II HRR, enrolled patients with significant mitral 
regurgitation of either FMR or DMR etiology. The long term echocardiographic and clinical outcomes of FMR patients enrolled in the EVEREST trials 
have not been previously presented.
Methods:  122 patients with FMR were enrolled in the EVEREST Clinical trials. Echocardiographic measures of MR grade and left ventricular (LV) 
function were measured by the Echocardiographic Core Lab at UCSF at baseline, 12, 18, and 24 months. Clinical benefit as determined by NYHA 
Functional Class was evaluated at similar time points.
Results:  Mitral regurgitation was reduced and sustained in the majority of FMR patients in the EVEREST trials following the MitraClip procedure. 
Left ventricular reverse remodeling was observed at 12 months in this patient group as evident by a reduction in LVEDV and LVESV. Importantly, 
the observed LV reverse remodeling was sustained at 18 and 24 months. Clinical outcomes improved in this patient population as evident by an 
improvement in NYHA Functional Class which was sustained through 24 months (table, data presented on an ITT basis). 
Baseline 12 months 18 months 24 months
MR≤2+, %
4.9
(n=122)
77.4
(n=93)
74.7
(n=79)
83.3
(n=66)
NYHA I/II, %
21.3
(n=122)
83.7
(n=92)
83.5
(n=79)
90.8
(n=65)
LVEDV, ml
(mean±SD)
176.8±45.4
(n=120)
153±42.9
(n=91)
136.6±38.2
(n=74)
139.4±40.8
(n=62)
LVESV, ml
(mean±SD)
93.2±34.7
(n=120)
82.6±33.5
(n=91)
73.9±30.6
(n=74)
73.6±31.4
(n=62)
Conclusion: These data suggest that FMR patients benefit from the MitraClip Therapy through 24 months of follow-up. A detailed analysis of 
outcomes on FMR patients will be presented, including stratification by left ventricular dysfunction, and surgical risk status.
